Updates from GKF

The Gauri Kaul Foundation, under the visionary leadership of Professor Upendra Kaul, is committed to achieving equality and equity in patient treatment. The foundation’s mission is to ensure that groundbreaking, evidence-based medicines are accessible to all, particularly those in underserved regions.

One of the foundation’s significant initiatives is the introduction of revolutionary treatments for heart failure, diabetes, and kidney protection. These new therapies are now available to the residents of Hawl, Pulwama, Shopian and Kulgam through the Prasad Joo Khan Heart Centre. Among these innovative medications are oral semaglutide, vericiguat, and finerenone, which have shown remarkable efficacy in improving patient outcomes.

Oral semaglutide represents a major advancement in diabetes management, offering a convenient and effective oral option for blood sugar control besides helps in weight reduction. Vericiguat is a novel drug that provides new hope for patients with heart failure, improving heart function and reducing hospitalizations. Finerenone is a cutting-edge treatment that protects kidney function, particularly in patients with diabetes, addressing a critical need in managing chronic conditions.

The Gauri Kaul Foundation believes that everyone has the right to the best possible healthcare and this initiative underscores the foundation’s commitment to bridging the gap in healthcare disparities and ensuring that all individuals, regardless of their location or socioeconomic status, receive the highest standard of medical care.

(All medicines should be taken ONLY under the supervision of your doctor.)